Dr. Xiaoyan Ke: Sharing International Advances and Comprehensive Treatment Experience in Lymphoma/Myeloma Diagnosis and Therapy

Dr. Xiaoyan Ke: Sharing International Advances and Comprehensive Treatment Experience in Lymphoma/Myeloma Diagnosis and Therapy

On July 20, the 5th Lymphoma & Myeloma Immunotherapy and Targeted Therapy Conference, along with the Gaobo Medical Academic Conference, was grandly held in Beijing. With the core concepts of "Precision, Integration, Innovation," the conference closely followed the latest developments and frontier topics from the 29th European Hematology Association (EHA 2024) and the 2024 American Society of Clinical Oncology (ASCO) annual meetings. To deepen the exchange and discussion, Oncology Frontier - Hematology Frontier invited Dr. Xiaoyan Ke from the Peking University Third Hospital/Beijing GoBroad Hospital for an exclusive interview to discuss advancements in the field and share academic insights.
Dr. Jia Fan, Dr. Jian Zhou, and Dr. Xinrong Yang’s Team: ctDNA Detection for Postoperative Minimal Residual Disease in Liver Cancer

Dr. Jia Fan, Dr. Jian Zhou, and Dr. Xinrong Yang’s Team: ctDNA Detection for Postoperative Minimal Residual Disease in Liver Cancer

Liver cancer is a highly prevalent and poorly prognosed malignancy, with a postoperative recurrence rate as high as 60%-70%. Postoperative minimal residual disease (MRD) is the main culprit behind cancer recurrence and metastasis, but currently, methods to detect MRD in liver cancer are very limited. At the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, a prospective study reported by Dr. Jia Fan, Dr. Jian Zhou, and Dr. Xinrong Yang’s team from Zhongshan Hospital affiliated with Fudan University shows that circulating tumor DNA (ctDNA) can serve as an ideal marker for detecting postoperative MRD in liver cancer, effectively warning of recurrence and metastasis. Furthermore, ctDNA monitoring of MRD can guide postoperative adjuvant therapy decisions and monitor the efficacy of drug treatments, thereby aiding in the precise management of liver cancer throughout the postoperative period and significantly improving patient prognosis.
EHA Global Insight丨Dr. Igor Aurer: Updated Guidelines and Insights on HIV-Related Lymphoma Treatment

EHA Global Insight丨Dr. Igor Aurer: Updated Guidelines and Insights on HIV-Related Lymphoma Treatment

Patients with AIDS have a significantly higher risk of developing non-Hodgkin lymphoma (NHL) compared to the general population. To promote a deeper understanding and standardized treatment of AIDS-related lymphoma (ARL), a special session titled "ARL: EHA-ESMO Clinical Practice Guidelines" was held at the recent 29th Annual Meeting of the European Hematology Association (EHA 2024). Oncology Frontier - Hematology Frontier interviewed the session chair, Dr. Igor Aurer from the University Hospital Centre Zagreb and Medical School, University of Zagreb, Zagreb, Croatia. He discussed the pathogenesis of ARL, treatment challenges, key updates to the guidelines, practical clinical advice, and his outlook for next year's EHA meeting and advancements in hematology.
Dr. Jihao Zhou: Unveiling the Challenges and Progress in Angioimmunoblastic T-Cell Lymphoma (AITL)

Dr. Jihao Zhou: Unveiling the Challenges and Progress in Angioimmunoblastic T-Cell Lymphoma (AITL)

On July 20, the 5th Lymphoma & Myeloma Immunotherapy and Targeted Therapy Conference, along with the Gaobo Medical Academic Conference, was successfully held in Beijing. With the core concepts of "Precision, Integration, Innovation," the conference closely followed the latest developments and frontier topics from the 29th European Hematology Association (EHA 2024) and the 2024 American Society of Clinical Oncology (ASCO) annual meetings. To deepen the exchange and discussion, Oncology Frontier - Hematology Frontier invited Dr. Jihao Zhou from Shenzhen People's Hospital for an exclusive interview to discuss advancements in the field and share academic insights.
ISTH AWARD丨Pioneer in Platelet Research Shaping the Future of Hematology: Dr. Andreas Greinacher Receives the Grant Medal

ISTH AWARD丨Pioneer in Platelet Research Shaping the Future of Hematology: Dr. Andreas Greinacher Receives the Grant Medal

Dr. Andreas Greinacher, with over 35 years of extensive experience, has brought groundbreaking scientific discoveries to the field of hematology through his critical thinking and relentless curiosity. At the highly anticipated 2024 International Society on Thrombosis and Haemostasis (ISTH) Annual Meeting, he was awarded the prestigious Robert P. Grant Medal, showcasing his profound expertise and significant contributions to the field of thrombosis and hemostasis.
ISTH Award丨Pioneer in Hematology: Dr. David Lillicrap Receives the Harold R. Roberts Award

ISTH Award丨Pioneer in Hematology: Dr. David Lillicrap Receives the Harold R. Roberts Award

The International Society on Thrombosis and Haemostasis (ISTH) is an inclusive organization with a global perspective, providing a valuable platform for scholars from around the world to engage, interact, and collaborate. Dr. David Lillicrap, a professor in the Department of Pathology and Molecular Medicine at Queen's University in Canada, was honored with the Harold R. Roberts Award at the ISTH 2024 meeting. This award recognizes individuals who have steadfastly supported the mission of the ISTH Scientific and Standardization Committee (SSC) through selfless dedication and expertise. As an outstanding hematologist and researcher, Dr. Lillicrap enjoys high acclaim in the field and has held several leadership positions within ISTH, including the Chair of the ISTH SSC. The Roberts Award not only acknowledges his exceptional service to the ISTH SSC but also celebrates his extraordinary dedication and lasting contributions.
ISTH AWARD丨2024 Fundamental Research Career Development Award Winners in Hematology

ISTH AWARD丨2024 Fundamental Research Career Development Award Winners in Hematology

The International Society on Thrombosis and Haemostasis (ISTH) announced the winners of the 2024 Fundamental Research Career Development Awards at the conference. This award aims to recognize early-career researchers who have made outstanding achievements in basic research. By acknowledging and encouraging these young scientists' innovative ideas, ISTH hopes to support them on their path to independent research, thereby strengthening the field of basic research. Each awardee will receive a grant to support their research, training, and collaborative studies in their respective fields. This award program, meticulously planned by the ISTH Fundamental Research Working Group under the guidance of the Education Committee, is designed as a career development incentive for promising early-career researchers.
CDL·Issue 18

CDL·Issue 18

Diabetes and liver disease are common chronic diseases in China. They interact with each other in terms of pathogenesis, clinical manifestations, and therapeutic targets, often serving as mutual risk factors. Effective co-management can help reduce the disease burden. To support the development of diabetes and liver disease co-management in China, this journal, in collaboration with the China Diabetes and Liver Disease Co-Management Initiative (CDL), presents the CDL Literature Monthly Review. Each month, we share relevant literature on the mechanisms of disease, diagnostic and therapeutic advancements concerning diabetes combined with liver disease, and invite experts in the field to provide commentary. We hope this review offers valuable insights and assistance to researchers, clinical practitioners, and front-line medical workers engaged in scientific research and clinical treatment.
Chinese guidelines on the management of ascites in cirrhosis

Chinese guidelines on the management of ascites in cirrhosis

In 2023, the Chinese Society of Hepatology of the Chinese Medical Association updated the 2017 guidelines on managing ascites and associated complications in cirrhosis. These revised guidelines, now termed "Guidelines on the Management of Ascites in Cirrhosis," provide comprehensive recommendations for the diagnosis and treatment of cirrhotic ascites, spontaneous bacterial peritonitis (SBP), and hepatorenal syndrome (HRS). This article summarizes these guidelines, emphasizing the importance of evidence-based practices and individualized patient care.
2024 CACA Integrated Breast Cancer Conference |Unified Efforts for Comprehensive Care: Multidisciplinary Experts Discuss Breast Cancer Management ——Dr. Jiayi Chen

2024 CACA Integrated Breast Cancer Conference |Unified Efforts for Comprehensive Care: Multidisciplinary Experts Discuss Breast Cancer Management ——Dr. Jiayi Chen

The Chinese Anti-Cancer Association, adhering to the tenet of "prevention, screening, diagnosis, treatment, and rehabilitation," has launched the "Chinese Tumor Integrated Diagnosis and Treatment Guidelines." At the 2024 CACA Integrated Breast Cancer Conference, "Oncology Frontier" invited three authoritative experts from internal medicine, surgery, and radiotherapy—Dr. Man Li from The Second Hospital of Dalian Medical University, Dr. Yingying Xu from The First Hospital of China Medical University, and Dr. Jiayi Chen from Ruijin Hospital, Shanghai JiaoTong University School of Medicine—to discuss the comprehensive management of breast cancer patients under the theme of "Integration for Prevention, Screening, Diagnosis, Treatment, and Rehabilitation." Under the moderation of Dr. Wei Li from Jiangsu Province People's Hospital, the three experts explored key aspects of comprehensive breast cancer management from personalized treatment, multidisciplinary collaboration, minimally invasive techniques, to new advancements in radiotherapy, providing valuable practical experience and theoretical guidance for future breast cancer management.